Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
-
Upload
eurocto -
Category
Health & Medicine
-
view
137 -
download
2
Transcript of Carlo Di Mario - Recent Publications & Research in CTO: 2015-16
![Page 1: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/1.jpg)
Recent Publications & Research in CTO: 2015-16
Carlo Di Mario, MD, FESC, FACC, FRCPCarlotta Sorini Dini, MD
Univ. Florence & Careggi Hospital
![Page 2: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/2.jpg)
Manuscripts Published on CTO
0
20
40
60
80
100
120
2010 2011 2012 2013 2014 2015 2016
![Page 3: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/3.jpg)
• Epidemiology
• Physiology
• Outcome Data
• Predictors
• Technique
• Imaging
• Stents in CTO
CTO Published Manuscripts 2015-2016 : Rapid Review of the Recent CTO Literature
![Page 4: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/4.jpg)
CTO in 20.3% of angiographies in 4140 patients
January-October 2014, single high volume centre (Quebec)
Exclusion criteria: history of coronary artery bypass graft (CABG)
Treatment: 9% PCI, 34% CABG, 57% medical therapy
NSTEMI41%
Stable CAD48%
STEMI8%
Other3%
Clinical presentation Viability testing
Viability68%
No viability6%No testing
26%
Azzalini et al In press Am J Cardiol 2016
![Page 5: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/5.jpg)
Azzalini et al In press Am J Cardiol 2016
Indipendent predictors of PCI
Success PCI : 64.6%
![Page 6: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/6.jpg)
ACCF/AHA/SCAI guidelines for PCI
![Page 7: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/7.jpg)
European Heart Journal (2015)36, 3189–3198
IRCTO is a prospective real world multicentre registrya total of 1777 patients were enrolled for an overall CTO prevalence of 13.3%.12 high-volume Italian centresStrategies: MT(medical therapy) in 826 patients (46.5%), PCI in 776 patients (43.7%), and CABG in the remaining 175 patients (9.8%) 1-year follow-up: patients undergoing PCI showed:
A) lower rate of major adverse cardiac and cerebrovascular events (MACCE) (2.6% vs. 8.2% and vs. 6.9%;P.0.001 and P.0.01) and cardiac death (1.4% vs. 4.7% and vs. 6.3%; P.0.001 and P.0.001) in comparison with those treated with MT and CABG, respectively.
B) after propensity score matching analysis, patients treated with PCI showed lower incidence of cardiac death (1.5 vs. 4.4% P.0.001), acute myocardial infarction (1.1 vs. 2.9% P 0.03), and re-hospitalization (2.3 vs. 4.4% P 0.04) in comparison with those managed by MT
![Page 8: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/8.jpg)
European Heart J: Sept 2015
Angiographic characteristics of CTO
![Page 9: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/9.jpg)
Am J Cardiol. 2016 Apr 1;117(7):1031-8
2368 patients with coronary heart disease and diabetes mellitus enrolled in the BARI-2D trial
Revascularization + intensive medical therapy ( PR) vs intensive medical therapy alone (IMT)
CTO prevalence 41 % (972 patients)
482 patients (41%) in PR group and 490 patients (41%) in IMT group
In the PR group, patients with CTO were more likely to be selected for the coronary artery bypass grafting stratum (CABG 62% vs PCI 31%, p <0.001)
![Page 10: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/10.jpg)
Single centre COMMIT-HF registry
January 2009-Dicember 2014
Follow-up: 12 months
consecutive nonselected patients hospitalized in cardiology wards and
intensive cardiac care units with a diagnosis of systolic HF
278 patients (41.2%) with CTO
The patients with CTO had a higher prevalence of previous MI (77% vs 66%)
and CABG (38% vs 26%)
Tajstra, Pyka et al J Am Coll Cardiol Intv 2016:9:1790-7
![Page 11: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/11.jpg)
Tajstra, Pyka et al J Am Coll Cardiol Intv 2016:9:1790-7
PCI only in 4.4% patients
NO viability testing was performed
![Page 12: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/12.jpg)
1212 patients with an EF of 35% or less and coronary artery disease amenable to CABG. Randomized to CABG plus medical therapy (n=610 ) or medical therapy alone (n=602 )
Velazquez, Kerry et al N Engl J Med 2016
![Page 13: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/13.jpg)
European Heart Journal , Sept 2016
![Page 14: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/14.jpg)
European Heart J , Sept 2016
![Page 15: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/15.jpg)
• Epidemiology
• Physiology
• Outcome Data
• Predictors
• Technique
• Imaging
• Stents in CTO
CTO Published Manuscripts 2015-2016 : Rapid Review of the Recent CTO Literature
![Page 16: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/16.jpg)
Stuijfzand ,Eur Heart J Cardiovasc Imaging 2016 Sep 1
Even in the presence of angiographicallywell-developed collateral arteries, thevast majority of CTO patients with apreserved LVEF showed significantlyimpaired perfusion
76 patients with CTO and preserved LVEF
PET to assess myocardial blood flow (MBF) and coronary flow reserve
MBF of the target area during hyperaemia was significantly lower when compared with the remote area (1.37+0.37 vs. 2.63+0.71 mL /min/g, P 0.001)
![Page 17: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/17.jpg)
• Epidemiology
• Physiology
• Outcome Data
• Predictors
• Technique
• Imaging
• Stents in CTO
CTO Published Manuscripts 2015-2016 : Rapid Review of the Recent CTO Literature
![Page 18: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/18.jpg)
• 14,441 patients with CTO (16%) and 75,431 patients without CTO
• January 2005-January 2012
• CTO group vs non CTO group
• Follow-up mean: 3.1 years
Ramunddal, Hoebers et al J Am Coll Card Intv 2016;9: 1535-44
CTO indipendent predictor mortality
![Page 19: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/19.jpg)
Ramunddal, Hoebers et al J Am Coll Card Intv 2016;9: 1535-44
![Page 20: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/20.jpg)
Ramunddal, Hoebers et al J Am Coll Card Intv 2016;9: 1535-44
Risk long-term mortality Successful revascularisation
Successful revascularisation 54.4%
![Page 21: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/21.jpg)
Long-term impact of CTO successful recanalization on mortality
LP. Hoebers et al IJC 2015
![Page 22: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/22.jpg)
Thai, Catheter Cardiov Intv 85:781–794 (2015)
![Page 23: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/23.jpg)
= failure PCI
= success PCI
![Page 24: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/24.jpg)
LONG-TERM FOLLOW UP (median FU 30-month)
Coronary CTO in the nonculprit artery in patients presenting with ST- segment elevation myocardial infarction is associated with increased short- and long-term all-
cause mortality.
![Page 25: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/25.jpg)
480 STEMI patients with a CTO in a non-infarct-related artery
Henriques , EuroIntervention 2016;12:423-430
Mortality in STEMI patients with a single CTO stratified according to culprit-related artery
Mortality in STEMI patients with a single CTO stratified according to CTO-related artery
![Page 26: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/26.jpg)
http://www.exploretrial.com/background.html
José PS Henriques
![Page 27: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/27.jpg)
http://www.exploretrial.com/background.html
Additional PCI of a CTO located
in the LAD may improve LVEF
and clinical outcome during
follow up.
Results
![Page 28: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/28.jpg)
• Epidemiology
• Physiology
• Outcome Data
• Predictors
• Technique
• Imaging
• Stents in CTO
CTO Published Manuscripts 2015-2016 : Rapid Review of the Recent CTO Literature
![Page 29: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/29.jpg)
• Occlusion characteristics (stump/length/calcium/tortuosity)
J-CTO Score
Morino et al. JACC Cardiovasc Interv 2011
![Page 30: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/30.jpg)
CL score- clinical and lesion related score
Alessandrino, JACC Interv 2015
![Page 31: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/31.jpg)
Christopoulos, JACC Interv 2016
![Page 32: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/32.jpg)
Karatasakis, Internat J Cardiol 2016
![Page 33: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/33.jpg)
Data from 4 centers involving 240 consecutive
CTO lesions with pre-procedural coronary
computed tomography angiography were
analyzed.
Successful guidewire (GW) crossing ≤30 min
was set as an endpoint to eliminate operator bias
JACC Cardiovasc Interv. 2015 Feb;8(2):257-67
![Page 34: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/34.jpg)
JACC Cardiovasc Interv. 2015 Feb;8(2):257-67
Conclusion: the CT-RECTORscore represents a simple andaccurate noninvasive tool forpredicting time-efficient GWcrossing that may aid in gradingCTO difficulty before PCI.
![Page 35: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/35.jpg)
Suzuki, Cathet Cardiov Interv 2016
Crossing success: 77%
PCI success: 68%
![Page 36: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/36.jpg)
• Epidemiology
• Physiology
• Outcome Data
• Predictors
• Technique
• Imaging
• Stents in CTO
CTO Published Manuscripts 2015-2016 : Rapid Review of the Recent CTO Literature
![Page 37: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/37.jpg)
Wilson WM, Walsh SJ, Yan AT, et al. Heart 2016;102:1486– 1493.
First attempt success rate by a hybrid-trained CTO operator was 79%.The success rate during the subsequent procedure was 87%
1,211 patients, 7 hospital in UK
Hybrid approach improves success of chronic totalocclusion angioplasty
![Page 38: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/38.jpg)
Hybrid approach improves success of chronic totalocclusion angioplasty
1,211 patients, 7 hospital in UK
Adverse eventsFinal strategy adopted
AWE= anterograde wire escalationADR= anterograde dissection re-entryRWE= retrograde wire escalationRDR= retrograde dissection re-entry
Wilson WM, Walsh SJ, Yan AT, et al. Heart 2016;102:1486– 1493.
![Page 39: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/39.jpg)
•44 european hospitals•8647 patients ,mean age was 62.0 ± 10.4 years,men 88.5%•Mean clinical follow-up duration was 24.7 ± 15.0 months
Galassi, Sianos et al JACC 2015, vol 65, n 22
![Page 40: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/40.jpg)
Galassi, Sianos et al JACC 2015, vol 65, n 22
Changes in angina and dyspnea status after retrograde CTO PCI
![Page 41: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/41.jpg)
• Epidemiology
• Physiology
• Outcome Data
• Predictors
• Technique
• Imaging
• Stents in CTO
CTO Published Manuscripts 2015-2016 : Rapid Review of the Recent CTO Literature
![Page 42: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/42.jpg)
J Am Heart Assoc. 2016;5
619 CTO PCI performed in 7 US centers
In 38 % patients was used intravascular imaging (IVUS in 36%, OCT in 3%, and both in 1.45%)
![Page 43: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/43.jpg)
Morphological assessment of CTO:coronary CTangiography and IVUS
128 patients, 130 lesions analyzed with coronary CT angiography and IVUS
Positive remodelling
(33.8%)
Negative remodelling
(56.9%)
Collapse(9.2%)
Yamamoto et al Eur Heart CardiovascImaging. 2016 Apr
![Page 44: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/44.jpg)
Yamamoto et al Eur Heart J Cardiovasc Imaging. 2016 Apr 20
Positive remodelling(n=44)
Negative remodelling(n=74)
Collapse(n=12)
P value
Median age (years) 64.5 (51.3-71) 67 (58-75.3) 55 (49.5-61.8) 0.005
Occlusion length (mm) 10.4 (5.5-17.4) 10.7 (6.0, 20.5) 46.3 (19.0, 61.0) <0.001
IVUS remodelling index 1.24 (1.14, 1.33) 0.97 (0.80, 1.02) 0.89 (0.53, 0.95) <0.001
Proximal plaque burden 53.1 (46.2, 62.6) 59.1 (50.6, 65.0) 40.5 (31.5, 47.5) 0.001
Distal plaque burden 51.2 (38.9, 58.0) 57.1 (47.0, 65.6) 34.1 (21.4, 39.1) <0.001
Stent expansion (%) 96.2 94.8 91.3 0.76
Retrograde approach (%) 25 36.5 66 0.03
34%57%
9%
29%
40% 29% 41%
33%
25%Plaque type
= non-calcified= mixed = calcified
![Page 45: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/45.jpg)
Am J Cardiol. 2016 Mar 1;117(5):727-34
serial follow-up intravascular ultrasound (baseline and follow-up at 9 ± 2 months)
after DES implantation into 40 CTOs.
anterograde approach (82.5%), retrograde approach (17.5%)
Late-acquired stent malapposition
was seen in 17 patients (42.5%)
In 8 CTOs (20%), a part of the stent
was implanted into a subintimal
space; in these 8 patients, maximum
percent neointimal hyperplasia and
minimum lumen area was similar in
the subintimal segment compared
with the adjacent intraplaque
segment. The frequency of late-
acquired stent malapposition was
similar
![Page 46: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/46.jpg)
The distal reference, but not theproximal reference lumen CSA,increased significantly at follow-up(3.8 ± 2.0 to 5.1 ± 2.3 mm(2), p =0.0004)
Conclusion: after CTO treatment with DES, distal vessel enlargement was detected.Subintimal stenting after recanalization of CTO was not inferior compared withstenting within the plaque in terms of long-term morphologic impact
Am J Cardiol. 2016 Mar 1;117(5):727-34
![Page 47: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/47.jpg)
230 pts with CTO randomized 1:1 IVUS+angiography vs angiography
EuroIntervention 2015;10:1409-1417
The primary endpoint was in-stent late lumen loss (LLL) at one-year follow-up.
Follow-up with office visits or telephone contact to 24 months
![Page 48: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/48.jpg)
In-stent LLL in the IVUS-guided group was significantly lower compared to the angiography-guided group at one-year follow-up (0.28±0.48 mm vs. 0.46±0.68 mm, p=0.025), with a significant difference in restenosis of the "in-true-lumen" stent between the two groups (3.9% vs.13.7%, p=0.021)
The minimal lumen diameter and minimal stent cross-section area significantly and negatively correlated with LLL (all p<0.001).
The rates of adverse clinical events were comparable between the IVUS- and angiography-guided groups at two-year follow-up (21.7% vs. 25.2%, p=0.641).
EuroIntervention 2015;10:1409-1417
![Page 49: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/49.jpg)
Circ Cardiovasc Interv. 2015 Jul;8(7):
N-BES, Nobori biolimus
eluting stent;
R-ZES,Resolute
zotarolimus-eluting
stent
![Page 50: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/50.jpg)
Circ Cardiovasc Interv. 2015 Jul;8(7):
IVUS-guided CTO intervention significantly improved MACE rate during the
12 months after DES implantation when compared with conventional
No significant differences zotarolimus and biolimus eluting stents
![Page 51: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/51.jpg)
• Epidemiology
• Physiology
• Outcome Data
• Predictors
• Technique
• Imaging
• Stents in CTO
CTO Published Manuscripts 2015-2016 : Rapid Review of the Recent CTO Literature
![Page 52: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/52.jpg)
Kelbæk et al, EuroIntervention 2015;11:650-657
3 groups: - chronic TO (CTO; n=256)- non-chronic TO (n=292) - no occlusion (n=2.941)
Resolute zotarolimus-eluting stent (R-ZES)
![Page 53: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/53.jpg)
The rate of TLF at two years was not significantly different among patients in the
CTO (9.1%), TO (9.8%), and no occlusion (10.4%) groups (log-rank p=0.800);
neither were the components of TLF
Definite or probable stent thrombosis occurred more frequently in the TO group
(2.8% vs. 1.2% in the CTO and 1.1% in the group with no occlusion, p=0.027).
There were 10 late and six very late stent thrombosis events
Conclusions
Apart from a higher rate of stent thrombosis in patients with TO, patients with
totally occluded coronary arteries who receive revascularisation with an R-ZES
have clinical outcomes comparable to those who receive a similar stent in non-
occluded lesions
Kelbæk et al, EuroIntervention 2015;11:650-657
![Page 54: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/54.jpg)
Teewen et al Eurointervention 2014
First phase : randomized 51 pts SES vs 46 pts Endeavor (zotarolimus)Second phase: randomized 103 patients SES vs 104 patients Resolute (zotarolimus)
First phase NO significative differencestarget lesion revascularisation 12.2% vs. 19.6%, p=0.4target vessel failure 14.3% vs. 19.6%, p=0.68 definite or probable stent thrombosis 4.1% vs. 2.2%
Second phase NO significative differencestarget lesion revascularisation 10% vs. 5.9%, p=0.42target vessel failure 10% vs. 7.9 %, p=0.78 definite or probable stent thrombosis 1% vs. 0%
Target vessel failure
![Page 55: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/55.jpg)
First-Generation Versus Second-Generation DES in CTO: Two-Year Results of a Multicenter Registry
Ahn …Choi, August 2016
![Page 56: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/56.jpg)
Efficacy of second-generation DES is similar tothat of first-generation DES for patients with CTO
![Page 57: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/57.jpg)
Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents in OCT
National Korean registry
Primary endpoint: MACE (composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization)
Each component of MACE was also comparableamong the 3 stents.Independent predictors of MACE were diabetesmellitus, previous congestive heart failure, andleft circumflex CTO.
![Page 58: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/58.jpg)
• 40 consecutive patients with CTO treated with BVS• Population : male 78%, mean age 59.9±8.3 years, diabetics 30% • Mean J-CTO score was 1.6. • Results: a total of 63 BVS were implanted with an average number of
1.6 per patient, and an average scaffold length of 42.4±21.5 mm. • No device-related complications. • At follow-up (median time 556 days): no deaths, one late scaffold
thrombosis , one focal restenosis
EuroIntervention 2016;12:e144-e151
![Page 59: Carlo Di Mario - Recent Publications & Research in CTO: 2015-16](https://reader031.fdocuments.net/reader031/viewer/2022030123/58a4e4b11a28ab34318b74b5/html5/thumbnails/59.jpg)
• CTO Prevalence is increasing in the sicker, older patients studiedangiographically nowadays and depends on patientcharacteristics: it may reach up to 40% in diabetes/ischemic HFwith low EF
• New comparisons of successful and failed CTO revascularizationsuggest improvement of long term prognosis
• New predicting scores for estimating technical success in CTOPCI offer limited advantage over J-CTO
• Standardization of modern CTO recanalization techniques,achieves success rates approaching 90%
• Intravascular image can facilitate CTO PCI but is rarely used
• Type of DES have limited influence in MACE post CTOrecanalisation, with insufficient data to recommend BVS
Conclusions
EuroCTO Course 2015-2016 : Rapid Review of the Recent CTO Literature